|
Home Market Commentary Gold & Metals Exploration Diamonds In Canada Oil & Gas Review High Tech Focus Special Situations Market Indices Biotech About Us Subscribe Contact Us |
| ARCHIVED EDITORIALS |
| Send Page To a Friend | Thursday July 24, 2008 |
| Corporate Overview Most significantly, the company’s two leading multi-application in-development drugs (known as compounds) exhibit “blockbuster drug” potential – representing a prospective multi-billion dollar combined marketplace. read full article ... SuperAntibodies Offer InNexus Biotechnology the Fast-Track to Multi-Billion Dollar Markets February, 2005 InNexus Biotechnology Inc. (TSX V: IXS, NASD OTC BB: IXSBF) is a small but dynamic Canadian SuperAntibody developer that has made great strides since SmallCapMedia first began covering this story in early 2003. read full article ... International Wex: Investment Opinion and Corporate Assessment Research Report August, 2004 Since we last covered International Wex Technologies Inc. in the fall of 2003, the company has made significant strides towards the commercialization of its inaugural pain management drug, Tectin ™ . Developed for the multi-billion dollar global cancer pain market, Tectin ™ clearly has the potential to make Wex a rising star in the biopharmaceutical sector within a few short years. read full article ... Positive Validation Trial Results Will Bring ProtoKinetix One Major Step Closer To the Multi-Billion Dollar Monoclonal Antibody Market April, 2004 SmallCapMedia has chosen ProtoKinetix Inc. (NASD-OTC.BB-PKTX) for special consideration from a number of companies involved in the research and development of anti-cancer treatments. read full article ... |
|
